Pharming receives funding for development of new treatments for premature ageing diseases
Under an International Innovation Subsidy granted by SenterNovem, an agency of the Dutch Ministry of Economic Affairs, DNage has initiated a project with the Eberhard Karls University in Tubingen Germany, and Pyxis Discovery BV, to design new drug development tools aimed at discovery of new therapeutics to treat (premature) ageing diseases. In addition, DNage will collaborate with the Leiden University Medical Center to identify unique biomarkers of such diseases that will facilitate the clinical development of new therapies.
The Company has filed several patent-applications based on the work performed in this field during the past few years. It expects that this additional funding will accelerate its drug development program which involves the start of a clinical program later this year to test a new product (Prodarsan®) for the treatment of premature ageing diseases.
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.